Bemarituzumab Biosimilar – Anti-FGFR2 mAb – Research Grade

Reference:
Size

,

Isotype

IgG1, kappa

Brand

Product type

Clonality

Expression system

Applications

,

Product nameBemarituzumab Biosimilar - Anti-FGFR2 mAb - Research Grade
SourceCAS 1952272-74-0
SpeciesHumanized
Expression systemMammalian cells
Purity>85%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /SynonymsBemarituzumab,FPA-144,FPA114-A,FGFR2,anti-FGFR2
ReferencePX-TA1492
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody

Description of Bemarituzumab Biosimilar - Anti-FGFR2 mAb - Research Grade

Bemarituzumab Biosimilar – Anti- FGFR2 mAb – Research Grade

About Bemarituzumab biosimilar

Bemarituzumab is a humanized monoclonal antibody targeting the human fibroblast growth factor receptor 2b (FGFR2b). This humanized glycosylated biosimilar belong to the family of immunoglobulin G1- type. It blocks FGF ligand binding to the receptor, which causes the inhibition of downstream signaling pathways and promotes Antibody-dependent cell-mediated cytotoxicity (ADCC). Bemarituzumab induces receptor internalization and degradation.

About FGFR2b and FGF/FGFR pathway

FGFR2b is an isoform of fibroblast growth factor receptors. They are four signaling tyrosine kinase FGF receptors mediating interactions between cytosolic environment and mesenchyme. Activated FGFRs can phosphorylate tyrosine residues which are mediating specifically interaction with cytosolic adaptor proteins. FGFR2b receptor is overexpressed in 30% of HER2-negative Gastric and Gastroesophageal Cancers. Bemarituzumab is designed to target these specific cancer subtypes, which are using the FGF/FGFR pathway to promote transformation and proliferation of cells into tumors and to promote angiogenesis.

A research grade biosimilar

Bemarituzumab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use.

SDS-PAGE for Bemarituzumab Biosimilar - Anti-FGFR2 mAb

Bemarituzumab Biosimilar - Anti-FGFR2 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Bemarituzumab Biosimilar – Anti-FGFR2 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

Human CD332-FGFR2 recombinant protein
Antigen

Human CD332-FGFR2 recombinant protein

PX-P6097 420€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.






    Cart (0 Items)

    Your cart is currently empty.

    View Products